LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Kodu・Aktsiate loetelu・Coherus Oncology Inc

Coherus Oncology Inc

Suletud

SektorTervishoid

1.47 -3.29

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.46

Max

1.52

Põhinäitajad
By Trading Economics
Sissetulek	-278M -37M
Müük	-438K 12M
P/E Sektori keskmine	3.509 49.888
Aktsiakasum	-0.25
Kasumimarginaal	-300.041
Töötajad	145
EBITDA	7.9M -35M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+442.76% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-17M 242M
Eelmine avamishind	4.76
Eelmine sulgemishind	1.47

Uudiste sentiment

By Acuity

50%

154 / 344 Pingereas Healthcare

Coherus Oncology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. juuni 2026, 23:22 UTC

Tulu

Suurimad hinnamuutused turgudel

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3. juuni 2026, 23:09 UTC

Kuumad aktsiad

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3. juuni 2026, 20:51 UTC

Tulu

Costco Reports 15% Sales Growth in May

3. juuni 2026, 20:43 UTC

Tulu

Broadcom 2Q Revenue Climbs on AI Chip Demand

3. juuni 2026, 23:48 UTC

Market Talk

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3. juuni 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. juuni 2026, 23:35 UTC

Market Talk

Oil Futures Fall on Possible Technical Correction -- Market Talk

3. juuni 2026, 23:15 UTC

Market Talk

Tulu

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3. juuni 2026, 22:08 UTC

Kuumad aktsiad

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3. juuni 2026, 21:54 UTC

Market Talk

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3. juuni 2026, 21:18 UTC

Tulu

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3. juuni 2026, 21:15 UTC

Tulu

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3. juuni 2026, 21:13 UTC

Tulu

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3. juuni 2026, 21:13 UTC

Tulu

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3. juuni 2026, 21:12 UTC

Tulu

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3. juuni 2026, 21:09 UTC

Tulu

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3. juuni 2026, 21:03 UTC

Tulu

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3. juuni 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. juuni 2026, 20:43 UTC

Tulu

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3. juuni 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3. juuni 2026, 20:37 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3. juuni 2026, 20:35 UTC

Tulu

Broadcom Stock Falls Despite Record Results -- Barrons.com

3. juuni 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3. juuni 2026, 20:17 UTC

Tulu

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3. juuni 2026, 20:17 UTC

Tulu

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3. juuni 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3. juuni 2026, 20:15 UTC

Tulu

Broadcom 2Q Adj EPS $2.44 >AVGO

3. juuni 2026, 20:15 UTC

Tulu

Broadcom 2Q EPS $1.91 >AVGO

3. juuni 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3. juuni 2026, 20:15 UTC

Tulu

Broadcom 2Q Rev $22.19B >AVGO

Võrdlus sarnastega

Hinnamuutus

Coherus Oncology Inc Prognoos

Hinnasiht

By TipRanks

442.76% tõus

12 kuu keskmine prognoos

Keskmine 8.25 USD 442.76%

Kõrge 12 USD

Madal 4 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Coherus Oncology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Coherus Oncology Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

154 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.